Ibogaine in Texas: What State Law and Programs Say

Ibogaine treatment Texas searches lead to a state research program, not to a treatment a person can enroll in today. In the official sources we read on 30 October 2026, ibogaine is still listed as a controlled substance in both federal regulation and the Texas Controlled Substances Act, and the state health agency's own page gives no way to enroll in anything. A 2025 Texas law set up a route to FDA-approved clinical trials, but that page says the plans submitted so far do not meet the law's requirements, and in March 2026 the Lieutenant Governor and the House Speaker said no drug company had submitted a proposal that met them and that Texas would proceed with its own research program. This page sets out what each source says, what it does not say, and what to check. It is general information, not legal or medical advice, and it does not say whether any clinic or program is legal.

What Texas passed in 2025

Texas Senate Bill 2308 added Chapter 491, "Ibogaine Treatment," to the Health and Safety Code. Chapter 491 lets the Health and Human Services Commission (HHSC) select a consortium to run ibogaine clinical trials aimed at FDA approval for opioid use disorder, co-occurring substance use disorder and other neurological or mental health conditions. The consortium must include a drug developer, a university and a hospital, and only universities or hospitals may serve as trial sites. The chapter also bars HHSC from paying out state funds until matching funds from non-state sources have been received and verified.

Governor Abbott signed the bill on 11 June 2025. His office's release says the law authorizes an FDA-approved clinical drug trial, that HHSC may provide state matching funds, and that the trial is to be managed by a public university in partnership with a drug company and a hospital.

Chapter 491 also has a treatment subchapter, but it applies only if the FDA has approved ibogaine to treat a medical condition. It then requires a licensed physician to supervise administration at a hospital or other licensed facility, and it says it does not preclude a physician from administering ibogaine in accordance with federal law.

Where the program stands

The HHSC page on ibogaine clinical trials says the agency selected UTHealth Houston as the lead institution and began contract development, but that recent plans submitted to HHSC do not meet the requirements of Chapter 491, including those about matching state funds and the allocation of revenue from intellectual property and other rights. The page shows no date. It says the full list of consortium members and contact information for people interested in enrolling will be posted later, and when we read it, it gave no enrollment contact.

A university release dated 15 December 2025, carried on the Texas Medical Center site, described a consortium called IMPACT, led by UTHealth Houston with the University of Texas Medical Branch, planning a two-year multicenter trial for addiction, traumatic brain injury and other behavioral health conditions. It said the grant requires non-state matching funds and gave no enrollment criteria or timeline.

On 31 March 2026 the Lieutenant Governor and the House Speaker said HHSC had reported that no drug company had submitted a proposal meeting the law's requirements and standards for state funds, said Texas would proceed with its own research program, and described $50 million allocated for ibogaine research. Because the HHSC page is undated, we cannot tell how these items fit in time, and the plans may have changed since.

What Texas criminal law says

Ibogaine is also named in the Texas Controlled Substances Act. Section 481.103 of the Health and Safety Code lists it in Penalty Group 2, among the hallucinogenic substances. Section 481.116 in the same chapter makes knowingly or intentionally possessing a Penalty Group 2 substance an offense, graded by weight from a state jail felony for under one gram to a first-degree felony for 400 grams or more. The section also says possession is not an offense if the substance was obtained directly from, or under a valid prescription or order of, a practitioner acting in the course of professional practice.

This page does not say how that exception applies to ibogaine, which federal regulation lists among the Schedule I hallucinogenic substances in 21 CFR 1308.11.

What this does and does not mean for a person in Texas

Funding and a trial framework are not access. Nothing we read makes ibogaine treatment available in Texas outside an approved trial: the treatment subchapter waits for FDA approval, and the HHSC page offers no enrollment path yet.

At the federal level, Executive Order 14401, signed on 18 April 2026, directs the FDA and the DEA to create a pathway under the Right to Try Act for eligible patients to access psychedelic drugs, including ibogaine compounds. It is a directive to agencies. We found no rule implementing it, and no source we read shows ibogaine removed from Schedule I.

One report of travel to Mexico

The Texas Tribune wrote on 31 March 2026: "For several years, people have silently traveled to clinics in Mexico to take ibogaine." That is the Tribune's own statement. It gave no numbers, we found no second source for it, and we have not verified it. The sentence does not say why anyone travels. This page makes no statement about Mexican law or about any clinic. Treatment outside Texas raises separate questions about law, medical oversight and travel that these sources do not answer.

What to check

• Whether the HHSC page now shows a signed contract, the consortium members and an enrollment contact, and what date any update carries. The page itself points people looking for mental health or substance use services to 2-1-1, option 5.
• Whether a trial you hear about is run by a university or hospital, as Chapter 491 requires for its trial sites, and where its enrollment rules are published.
• Whether a claim that something is "legal in Texas" names a statute or agency page and a date, and whether that source actually says it.
• Whether a physician who knows your heart history has weighed in, because of the cardiac risk described below.
• Personal legal questions belong with a Texas lawyer, and health questions with a qualified physician.

Heart risk

A 2026 review in the journal Addiction describes a rare but clinically significant risk of prolonged QTc interval and potentially fatal ventricular arrhythmias with ibogaine, reports published cardiac events at therapeutic doses including in people with no known heart disease, and calls for treatment only under controlled medical supervision with close monitoring of heart function. The abstract does not say that any setting is safe, and neither does this page.

How this page was made

We read each source named here on 30 October 2026. The HHSC page has no date. We read the Texas statutes, the bill and the executive order through automated summarizing fetches, and we read the federal regulation through a mirror because the official site blocks automated reading, so confirm each against the official text. The university's own site blocked automated reading, so its release was read on the Texas Medical Center site. We did not contact any agency, clinic or lawyer. Laws and programs change, so check current sources before relying on this page.